Fans of the film can now get their hands on an exclusive collection of products including a Limited-Edition Beetlejuice flavour, with more thrills to come. ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Today, Fanta® and Warner Bros. Pictures are excited to announce a global partnership ahead of the release of the highly anticipated movie Beetlejuice Beetlejuice – debuting in cinemas on September 6th, 2024. Manifesting the spirit of the mischievous demon, Fanta® and Warner Bros. Pictures are coming together to bring ...

文章核心观点 - 公司宣布其首款商业产品Ohtuvayre(ensifentrine)已在美国上市,这是20多年来首个用于治疗慢性阻塞性肺病(COPD)的新型吸入制剂 [3] - 公司正在积极推进Ohtuvayre的商业化,已与2,000多名医疗专业人士互动,并有100多名医生通过专门的药房开具了处方 [4] - 公司还计划在2024年第三季度启动一项针对非囊性纤维化支气管扩张症(NCFBE)患者的Ohtuvayre临床试验,以及一项针对COPD的吸入式固定剂量联合制剂的临床试验 [5] 财务和运营情况 - 公司在2024年6月30日的现金及现金等价物余额为4.046亿美元,足以支持公司计划的运营和资本支出,包括Ohtuvayre的商业化 [7] - 研发费用同比增加2,190万美元,主要是由于支付了6.3百万美元的里程碑费用、股份支付费用增加以及与预上市库存生产相关的费用 [8] - 销售、一般及管理费用同比增加3,660万美元,主要是由于支付了1,500万美元的里程碑费用、营销和其他商业化活动费用增加以及人员成本上升 [8] - 公司在2024年第二季度录得7,080万美元的净亏损,主要是由于上述费用的增加 [9] 公司发展计划 - 公司已于2024年6月在美国获得Ohtuvayre的批准,并开始商业化销售 [6] - 公司已提交了用于Ohtuvayre的J码申请,预计将于2025年1月获得永久性的产品专用J码 [6] - 公司已完成6.5亿美元的战略性融资,包括4亿美元的债务融资和2.5亿美元的收益权融资,为未来发展提供了充足的资金支持 [6][7] - 公司计划在2024年下半年在欧洲呼吸学会国际大会和CHEST年会上发表关于Ohtuvayre III期临床试验的进一步分析结果 [5]

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

VEON 2Q24 Trading Update: Double-Digit USD Growth, Robust Operational Execution, Confirming Full Year Guidance Amsterdam, 8 August 2024 07:00AM CEST VEON Q2 2024 Highlights Q2 revenue of USD 1,026 million, +12.1% YoY (+15.1% YoY in local currency) and EBITDA of USD 459 million, +10.6% YoY (+13.9% YoY in local currency) Q2 direct digital revenue of USD 108 million, +83.3% YoY (+81.4% YoY in local currency) Q2 capex of USD 181 million, +5.8% YoY, with LTM capex intensity of 18.0% Total cash and cash equivalen ...

文章核心观点 - 公司发行2.25%到期日为2029年的可转换优先票据,总金额为2.75亿美元,并授予承销商增发4.125亿美元的选择权 [1][2] - 公司将使用部分募集资金偿还现有的有担保贷款,并将与银行签订新的有担保贷款协议 [5] - 公司还将使用部分募集资金购买与可转换票据相关的套期保值交易 [6][7][9][10] 公司概况 - 公司是一家多元化的生物制药公司,专注于开发、生产和销售高质量的处方药品,包括罕见疾病领域 [12] - 公司正在通过其主要产品Purified Cortrophin® Gel扩大罕见疾病业务,并加强仿制药业务的研发能力,同时在成熟品牌领域实现创新 [12] 融资交易 - 公司预计本次发行的净募集资金约为2.668亿美元,如果承销商行使增发选择权,则净募集资金约为3.068亿美元 [5] - 公司将使用约3530万美元的净募集资金购买与可转换票据相关的套期保值交易 [5][6][7][9][10] - 剩余的净募集资金将与公司现金一起用于偿还现有的有担保贷款 [5]

(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated) VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) ("Fortuna" or the "Company") today reported its financial and operating results for the second quarter of 2024. Second Quarter 2024 highlights Financial Attributable net income of $40.6 million or $0.13 per share, compared to a $26.3 million or $0.09 per share in Q1 2024 Adjusted attributable net income1 of ...

TORONTO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) today reported its second quarter (Q2) and half year (H1) results for the period ended June 30th, 2024. "I'm delighted that this quarter was the most profitable since 2016 as measured by Adjusted EBITDA(1) for our mining operations and Q3 is off to a good start. Production costs increased 8% quarter-overquarter, but revenue grew by 38%. Fox and Gold Bar are capitalizing on the higher gold prices to increase operating cash f ...

HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission. The filing can be viewed through a link on FibroBiologics' website at https:/ ...

HOUSTON, Aug. 7, 2024 /PRNewswire/ -- Quanta Services, Inc. (NYSE: PWR) ("Quanta") announced today the pricing of its offering (the "Offering") of (i) $600,000,000 aggregate principal amount of 4.75% senior notes due 2027 (the "2027 Notes") at a price to the public 99.818% of their face value, and (ii) $650,000,000 aggregate principal amount of 5.25% senior notes due 2034 (the "2034 Notes" and, together with the 2027 Notes, the "Notes") at a price to the public 99.409% of their face value. The Offering is e ...

SPOKANE, Wash., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Avista Corp.'s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.475 per share on the company's common stock. The common stock dividend is payable September 13, 2024, to shareholders of record at the close of business on August 22, 2024. The declaration of dividends is at the sole discretion of the board of directors. The board considers the level of dividends on a regular basis, taking into account numerous factors, including financial ...